APAlejandro Martínez Pradeda

Alejandro Martínez Pradeda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alejandro Martínez Pradeda has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SiMON-PRO-Hematology®: Digital techology for pharmacotherapeutic and patient reported outcomes monitoring in patients with hematologic malignancies

    by Alejandro Martínez Pradeda, Elena Fernández Gabriel, Sergio Jimeno Aguado, Ana Sanclaudio Luhia, Víctor Noriega Concepción, Luis Margusino-Framiñán

  • Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes

    by Alejandro Martínez Pradeda, Pablo Feijoo Vilanova, Elena Fernández Gabriel, Víctor Giménez Arufe, Ana María Vale López, Jorge Suanzes-Hernández, Luis Margusino-Framiñán, Víctor Noriega Concepción

    Background: Ibrutinib has transformed chronic lymphocytic leukemia (CLL) treatment, offering significant survival benefits in clinical trials. However, real-world evidence is essential to understand its safety and efficacy in broader patient populations. Objective: To evaluate ibrutinib safety and effectiveness in a real-world cohort of CLL patients focusing on dose reductions, adverse events, and survival outcomes. Methods: This single-center, retrospective, observational study of CLL patients treated with ibrutinib was conducted between January 2015 and June 2023. Data were retrieved from the IANUS electronic medical records including patient demographics, treatment indications, genetic markers, comorbidities, adverse events, and dose changes. Results: This study involved 90 patients with a median age of 71.5 years. Most patients presented with advanced-stage disease (BINET C: 46%, RAI IV: 25%). Cardiovascular comorbidities were common (70%) and 11% had prior bleeding events. Severe adverse events (grade 3-4) occurred in most patients (60%) with infections (33.3%) and neutropenia (14.4%) being the most common. Dose reductions were required in 11.1% of patients mainly due to hematological toxicities and 22% discontinued treatment due to adverse events. However, dose reductions and severe adverse events did not significantly affect overall survival or progression-free survival. The overall response rate was 82.2%, with 42.2% achieving complete remission. Multivariate analysis identified age and comorbidities as significant predictors of severe adverse events but not survival outcomes. Conclusion and Relevance: Ibrutinib remains an effective treatment for lymphocytic leukemia, even in patients with comorbidities and high-risk genetic characteristics. The study supports dose adjustment as a viable strategy for managing toxicities without compromising efficacy. These findings highlight the need for personalized care and proactive management of adverse events in clinical practice, particularly in elderly patients or those with multiple comorbidities. Long-term clinical studies are essential to refine treatment strategies and improve patient outcomes.


  • Open Access

    Effect of Gender on Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Real-World Study

    by Teresa Calleja-Chucla, Patricia Cordeiro González, Alejandro Martínez Pradeda, Sonia Pértega-Díaz, Luis Margusino-Framiñán, Silvia Antolín Novoa

    Objective: To evaluate the differences in overall survival (OS) and progression-free survival (PFS) between men and women with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in second-line and later treatments. Methods: A retrospective, single-center observational study was conducted on patients with advanced NSCLC treated with ICIs (nivolumab, pembrolizumab, and atezolizumab) from January 2015 to December 2019 (with follow-up until December 2021). Demographic, clinical, and treatment-related variables were collected. OSand PFSwere analyzed using the Kaplan–Meier method and compared between genders using the log-rank test.A multivariate Cox regression analysis was performed to adjust for confounders. Results: A total of 189 patients were included, and 47 (25%) were women. The most common histology was adenocarcinoma (61%). Women began treatment at a younger age (59.8 vs. 66 years, p < 0.001) and had higher rates of active smoking (46.8% vs. 38%, p = 0.001). The median OS was similar between men (9.5 months, 95% CI: 7.1–11.8) and women (9.2 months, 95% CI: 3.3–15.2; p = 0.382) while PFS was significantly higher in males (3.2 months, 95% CI: 2.5–4.0) than in females (2.1 months; 95% CI = 1.6–2.5) (p = 0.002).Women had higher rates of tumor cachexia (BMI < 20).Worse PFS was observed for women both in the = 25 kg/m2, median OS was higher in women than in men (14.7 months vs. 10.1 months). Women had also a significantly worse PFS than men among those with a cumulative tobacco consumption of = 2 was significantly associated with both worse OS (HR = 3.53; 95% CI = 1.93–6.47) and PFS (HR = 2.19; 95% CI = 1.23–3.89). Women who discontinued due to toxicity (n = 7) had a median OS of 41.4 months (95% CI: 14.7–68.1) after discontinuation, whereas men (n = 15) had a median OS of 8.8 months (95% CI: 6.9–10.8), (p = 0.045). Conclusions: Sex-based differences were observed in the ICI outcomes. Women had worse PFS, particularly with lower BMI and lower tobacco exposure, despite similar OS between sexes. Women discontinued ICIs due to toxicity earlier but showed longer OS after discontinuation. Poor ECOG status was linked to worse outcomes across all the patients.


  • Open Access

    Observational Study to Compare Biological Drug Concentration Quantification Techniques and Immunogenicity in Patients with Immune-Mediated Diseases

    by Alejandro Martínez-Pradeda, Laida Elberdín, Ángeles Porta-Sánchez, María Outeda, Mª Teresa Diz-Lois Palomares, Teresa Vázquez-Rey, Benito González-Conde, Emilio Estévez-Prieto, María I. Gómez-Besteiro, Isabel Martín-Herranz

    Measuring biological drugs’ trough concentrations and the concentrations of anti-drug antibodies is a valuable practice for treatment optimization. ELISA techniques are the gold standard for biological drug concentration quantification, but new techniques such as chemiluminescence immunoassays present some advantages. The aim of this unicentric prospective observational study is to compare the infliximab, adalimumab, vedolizumab and ustekinumab trough levels and anti-adalimumab and anti-infliximab antibodies concentrations obtained when using a chemiluminescent instrument (i-TRACK®, Theradiag, Croissy-Beaubourg, France) and an ELISA instrument (TRITURUS®, Griffols, Barcelona, Spain). Linear regression, Pearson or Spearman tests, Bland–Altman plots and the Cohen kappa test were applied for every sample. The correlation was excellent for both assays in the measurement of all drug concentrations. In general, values were lower when measured using i-TRACK than when using TRITURUS, especially when the values were high. Both techniques proved valuable in clinical practice for monitoring adalimumab and infliximab drug concentration. However, the results were modest for ustekinumab and vedolizumab, so caution is recommended and further research is needed. The limited number of anti-drug antibody-positive samples precluded a comparison between the techniques.


  • Open Access

    Analysing Early Diagnosis Strategies for HIV Infection: A Retrospective Study of Missed Diagnostic Opportunities

    by Víctor Giménez-Arufe, Sandra Rotea-Salvo, Alejandro Martínez-Pradeda, Álvaro Mena-De-Cea, Luis Margusino-Framiñán, Jorge Suanzes-Hernández, María Isabel Martín Herranz, Purificación Cid-Silva

    Early diagnosis of a Human Immunodeficiency Virus (HIV)-infected person represents a cornerstone of HIV prevention, treatment, and care. Numerous publications have developed recommendations where HIV serology is indicated to reduce missed diagnostic opportunities (MDOs). This retrospective study analyses new HIV infection diagnoses and the relationship between late diagnosis (LD)/advanced HIV disease (AHD), baseline characteristics, and MDOs. Sociodemographic data and data related to contact with the health system in the 5 years before diagnosis were collected. Most of the 273 diagnoses were made in primary care (48.5%). Approximately 50.5% and 34.4% had LD and AHD criteria, respectively. Female sex was associated with a higher incidence of LD. Persons infected through the heterosexual route and those at an older age had a higher risk for LD and AHD. People with previous HIV serology presented a lower percentage of LD and AHD. In total, 10% of the health contact instances were classified as MDOs, mostly occurring in primary care. A significant increase in the median of MDOs was observed in patients with LD/AHD. Female sex and hepatitis C virus co-infection were associated with an increase in the number of MDOs. The high percentage of LD and AHD and the significant number of MDOs show that the current screening system should be improved.